- Home
- SBFG vs YARW Comparison
SBFG vs YARW Comparison
Compare SBFG & YARW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SBFG | YARW |
|---|---|---|
| Founded | 1983 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 182.2M | 154.5M |
| IPO Year | 2014 | 2017 |
Fundamental Metrics
Financial Performance| Metric | SBFG | YARW |
|---|---|---|
| Price | $29.55 | $20.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $57.00 |
| AVG Volume (30 Days) | 8.2K | ★ 97.6K |
| Earning Date | 10-22-2026 | 11-03-2026 |
| Dividend Yield | ★ 2.18% | N/A |
| EPS Growth | 27.33 | ★ 33.33 |
| EPS | ★ 1.41 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.46 | N/A |
| Revenue Next Year | $2.35 | N/A |
| P/E Ratio | $20.67 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $18.16 | $18.05 |
| 52 Week High | $30.84 | $44.28 |
Technical Indicators
Market Signals| Indicator | SBFG | YARW |
|---|---|---|
| Relative Strength Index (RSI) | 49.52 | 39.65 |
| Support Level | $28.40 | $18.24 |
| Resistance Level | $30.43 | $32.89 |
| Average True Range (ATR) | 0.87 | 1.97 |
| MACD | -0.09 | 0.26 |
| Stochastic Oscillator | 54.41 | 32.07 |
Price Performance
Historical ComparisonAbout SBFG SB Financial Group Inc.
SB Financial Group Inc that provides a range of community banking services, including commercial and consumer lending, personal and business banking, treasury management and merchant services, personal wealth management and brokerage services, and other financial services to individuals, businesses, and municipalities. It operates in a single segment, which is Banking.
About YARW Yarrow Bioscience Inc. Common Stock
Yarrow Bioscience Inc is a clinical-stage biopharmaceutical company focused on developing biotherapeutics for autoimmune thyroid diseases. Its flagship product candidate, YB-101 (also known as GenSci098), is a humanized, monoclonal antibody targeting the thyroid-stimulating hormone receptor, which Yarrow plans to develop for the treatment of Graves' disease (GD) and potentially thyroid eye disease (TED). The company has one reportable segment relating to the research and development of its research programs, GD and TED.